State of Wisconsin Investment Board bought a new position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 18,000 shares of the specialty pharmaceutical company’s stock, valued at approximately $225,000. State of Wisconsin Investment Board owned about 0.06% of Collegium Pharmaceutical at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in COLL. Teachers Advisors LLC lifted its position in Collegium Pharmaceutical by 18.1% in the 4th quarter. Teachers Advisors LLC now owns 25,437 shares of the specialty pharmaceutical company’s stock worth $396,000 after buying an additional 3,892 shares during the last quarter. Nationwide Fund Advisors lifted its position in Collegium Pharmaceutical by 16.4% in the 1st quarter. Nationwide Fund Advisors now owns 10,087 shares of the specialty pharmaceutical company’s stock worth $101,000 after buying an additional 1,422 shares during the last quarter. Wells Fargo & Company MN lifted its position in Collegium Pharmaceutical by 404.1% in the 1st quarter. Wells Fargo & Company MN now owns 86,776 shares of the specialty pharmaceutical company’s stock worth $873,000 after buying an additional 69,563 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Collegium Pharmaceutical by 6.1% in the 1st quarter. Bank of New York Mellon Corp now owns 65,305 shares of the specialty pharmaceutical company’s stock worth $656,000 after buying an additional 3,775 shares during the last quarter. Finally, Trexquant Investment LP bought a new stake in Collegium Pharmaceutical in the 1st quarter worth approximately $259,000. Institutional investors own 83.13% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “State of Wisconsin Investment Board Buys New Stake in Collegium Pharmaceutical, Inc. (COLL)” was originally published by Daily Political and is owned by of Daily Political. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/09/16/state-of-wisconsin-investment-board-buys-new-stake-in-collegium-pharmaceutical-inc-coll.html.

A number of research firms recently weighed in on COLL. Zacks Investment Research downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Piper Jaffray Companies set a $14.00 target price on Collegium Pharmaceutical and gave the stock a “buy” rating in a research report on Tuesday, July 25th. ValuEngine upgraded Collegium Pharmaceutical from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. BidaskClub downgraded Collegium Pharmaceutical from a “hold” rating to a “sell” rating in a research report on Friday, August 4th. Finally, Janney Montgomery Scott restated a “buy” rating and issued a $25.00 target price on shares of Collegium Pharmaceutical in a research report on Monday, June 12th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $20.67.

Collegium Pharmaceutical, Inc. (COLL) opened at 10.58 on Friday. The firm has a 50-day moving average price of $10.61 and a 200-day moving average price of $12.13. Collegium Pharmaceutical, Inc. has a 52 week low of $10.15 and a 52 week high of $20.55. The stock’s market capitalization is $312.81 million.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings data on Wednesday, August 9th. The specialty pharmaceutical company reported ($0.72) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.81) by $0.09. The business had revenue of $3.56 million during the quarter, compared to analyst estimates of $4.07 million. Collegium Pharmaceutical had a negative return on equity of 93.73% and a negative net margin of 1,319.39%. Equities research analysts predict that Collegium Pharmaceutical, Inc. will post ($3.00) EPS for the current fiscal year.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting.

Want to see what other hedge funds are holding COLL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Collegium Pharmaceutical, Inc. (NASDAQ:COLL).

Institutional Ownership by Quarter for Collegium Pharmaceutical (NASDAQ:COLL)

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.